Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by TD Cowen

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. HC Wainwright upped their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Truist Financial reduced their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $32.64 on Monday. The company’s 50 day simple moving average is $35.85 and its 200 day simple moving average is $31.47. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -4.66 and a beta of 0.58. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. As a group, analysts anticipate that Agios Pharmaceuticals will post -5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at $25,000. Nykredit A S acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth about $26,000. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the 1st quarter worth about $40,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $49,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.